PMID- 29768412
OWN - NLM
STAT- MEDLINE
DCOM- 20180716
LR  - 20220716
IS  - 1935-2735 (Electronic)
IS  - 1935-2727 (Print)
IS  - 1935-2727 (Linking)
VI  - 12
IP  - 5
DP  - 2018 May
TI  - Adverse events following single dose treatment of lymphatic filariasis: 
      Observations from a review of the literature.
PG  - e0006454
LID - 10.1371/journal.pntd.0006454 [doi]
LID - e0006454
AB  - BACKGROUND: WHO's Global Programme to Eliminate Lymphatic Filariasis (LF) uses 
      mass drug administration (MDA) of anthelmintic medications to interrupt LF 
      transmission in endemic areas. Recently, a single dose combination of ivermectin 
      (IVM), diethylcarbamazine (DEC), and albendazole (ALB) was shown to be markedly 
      more effective than the standard two-drug regimens (DEC or IVM, plus ALB) for 
      achieving long-term clearance of microfilaremia. OBJECTIVE AND METHODS: To 
      provide context for the results of a large-scale, international safety trial of 
      MDA using triple drug therapy, we searched Ovid Medline for studies published 
      from 1985-2017 that reported adverse events (AEs) following treatment of LF with 
      IVM, DEC, ALB, or any combination of these medications. Studies that reported AE 
      rates by treatment group were included. FINDINGS: We reviewed 162 published 
      manuscripts, 55 of which met inclusion criteria. Among these, 34 were clinic or 
      hospital-based clinical trials, and 21 were community-based studies. Reported AE 
      rates varied widely. The median AE rate following DEC or IVM treatment was 
      greater than 60% among microfilaremic participants and less than 10% in persons 
      without microfilaremia. The most common AEs reported were fever, headache, 
      myalgia or arthralgia, fatigue, and malaise. INTERPRETATION: Mild to moderate 
      systemic AEs related to death of microfilariae are common following LF treatment. 
      Post-treatment AEs are transient and rarely severe or serious. Comparison of AE 
      rates from different community studies is difficult due to inconsistent AE 
      reporting, varied infection rates, and varied intensity of follow-up. A more 
      uniform approach for assessing and reporting AEs in LF community treatment 
      studies would be helpful.
FAU - Budge, Philip J
AU  - Budge PJ
AUID- ORCID: 0000-0002-0069-2372
AD  - Infectious Diseases Division, Department of Medicine, Washington University 
      School of Medicine in St. Louis, St. Louis, Missouri, United States of America.
FAU - Herbert, Carly
AU  - Herbert C
AD  - Department of Anthropology, Washington University in St. Louis, St. Louis, 
      Missouri, United States of America.
FAU - Andersen, Britt J
AU  - Andersen BJ
AUID- ORCID: 0000-0002-0946-013X
AD  - Infectious Diseases Division, Department of Medicine, Washington University 
      School of Medicine in St. Louis, St. Louis, Missouri, United States of America.
FAU - Weil, Gary J
AU  - Weil GJ
AUID- ORCID: 0000-0002-6336-3824
AD  - Infectious Diseases Division, Department of Medicine, Washington University 
      School of Medicine in St. Louis, St. Louis, Missouri, United States of America.
LA  - eng
GR  - K08 AI121422/AI/NIAID NIH HHS/United States
GR  - L30 AI113845/AI/NIAID NIH HHS/United States
GR  - K08AI121422/NH/NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180516
PL  - United States
TA  - PLoS Negl Trop Dis
JT  - PLoS neglected tropical diseases
JID - 101291488
RN  - 0 (Filaricides)
RN  - 70288-86-7 (Ivermectin)
RN  - F4216019LN (Albendazole)
RN  - V867Q8X3ZD (Diethylcarbamazine)
SB  - IM
MH  - Albendazole/administration & dosage/*adverse effects
MH  - Diethylcarbamazine/administration & dosage/*adverse effects
MH  - Drug Therapy, Combination
MH  - Elephantiasis, Filarial/*drug therapy
MH  - Filaricides/administration & dosage/*adverse effects
MH  - Humans
MH  - Ivermectin/administration & dosage/*adverse effects
PMC - PMC5973625
COIS- The authors have declared that no competing interests exist.
EDAT- 2018/05/17 06:00
MHDA- 2018/07/17 06:00
PMCR- 2018/05/16
CRDT- 2018/05/17 06:00
PHST- 2017/12/13 00:00 [received]
PHST- 2018/04/16 00:00 [accepted]
PHST- 2018/05/29 00:00 [revised]
PHST- 2018/05/17 06:00 [pubmed]
PHST- 2018/07/17 06:00 [medline]
PHST- 2018/05/17 06:00 [entrez]
PHST- 2018/05/16 00:00 [pmc-release]
AID - PNTD-D-17-01961 [pii]
AID - 10.1371/journal.pntd.0006454 [doi]
PST - epublish
SO  - PLoS Negl Trop Dis. 2018 May 16;12(5):e0006454. doi: 
      10.1371/journal.pntd.0006454. eCollection 2018 May.